Patents Examined by Kristina M Hellman
  • Patent number: 11541124
    Abstract: The invention relates to improvements in drug delivery and more particularly to the use of Cell Penetrating Agents (CPA's) or Cell Penetrating Peptides (CPP's) which have been stabilized by, for example: i) stapling two amino acids to form Stapled CPP's (StaP's) or ii) stitching three or more amino acids to form stitched CPP's (StiP's). These stabilized CPP's are conjugated to a drug or Biologically Active Compound (BAC) directly or via a Bi-Functional Linker (BFL) so that the BAC can be carried through a cell membrane by the CPP. The resulting molecules are referred to as Drug Carrying Cell Penetrating Molecules (DCCPM's). The preferred BAC is an electrically low charge carrying oligonucleotide such as a phosphorodiamidate morpholino oligonucleotide (PMO).
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: January 3, 2023
    Assignee: SUTURA THERAPEUTICS LTD
    Inventors: Keith Foster, Wouter Eilers, Adam James Reginald Gadd
  • Patent number: 11534382
    Abstract: The present invention relates generally to compositions and methods of using the same such as, for example, methods of treating the skin of a subject using a composition as described herein. The composition may comprise a diluent, a solvent, a penetration enhancing agent, a skin brightening agent, a skin renewing agent, a thickening agent, an anti-irritant, a chelating agent, an active pharmaceutical ingredient (API), optionally a pH adjustment agent, and optionally a preservative. The composition may further comprise L-arginine and/or L-citrulline and/or esters and/or derivatives thereof.
    Type: Grant
    Filed: June 19, 2018
    Date of Patent: December 27, 2022
    Assignee: Novan, Inc.
    Inventors: Nathan Stasko, Ryan Doxey
  • Patent number: 11524053
    Abstract: Provided are methods and compositions for treatment of angiogenic disorders using anti-VEGF agents. The anti-VEGF agents comprise VEGF binding domains and have the ability to bind vitreous. Provided are exemplary embodiments of Fc-IgG fusion proteins with VEGF binding domains with strong heparin-binding characteristics, strong inhibition of VEGF mitogenic activity, and improved pharmacokinetics, namely longer half-lives of the anti-VEGF agents and consequently less frequent dosing.
    Type: Grant
    Filed: January 25, 2019
    Date of Patent: December 13, 2022
    Assignee: The Regents of the University of California
    Inventor: Napoleone Ferrara
  • Patent number: 11524056
    Abstract: The present invention concerns Thymosin alpha 1 (T?1) for use in treatment of cystic fibrosis as a CFTR corrector, CFTR potentiator and anti-inflammatory agent.
    Type: Grant
    Filed: October 4, 2019
    Date of Patent: December 13, 2022
    Assignee: SciClone Pharmaceuticals International Ltd.
    Inventors: Luigina Romani, Enrico Garaci
  • Patent number: 11492385
    Abstract: Long-acting co-agonists of the glucagon and GLP-1 receptors are described.
    Type: Grant
    Filed: August 26, 2020
    Date of Patent: November 8, 2022
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Anandan Palani, Ravi Nargund, Paul E. Carrington, Tomi Sawyer, Qiaolin Deng, Antonello Pessi, Elisabetta Bianchi, Federica Orvieto
  • Patent number: 11485767
    Abstract: This invention provides methods and materials for treating cancer. The invention encompasses methods and materials for delivering programmed death-ligand 1 (PD-L1) binding compounds and/or compositions containing one or more monovalent or multivalent programmed death-ligand 1 (PD-L1) binding compounds which are administered to a mammal having cancer to treat the mammal. In some cases, a multivalent PD-L1 binding compound can include two or more programmed cell death protein 1 (PD-1) polypeptides (and/or fragments thereof having the ability to bind PD-L1). This invention also provides methods and materials for making multivalent PD-L1 binding compounds and methods and materials for making nucleic acid molecules that encode PD-L1 binding compounds.
    Type: Grant
    Filed: April 28, 2020
    Date of Patent: November 1, 2022
    Assignee: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
    Inventor: Michael A. Barry
  • Patent number: 11472856
    Abstract: The present disclosure features, at least in part, methods for conserving cell function, e.g., immune cell function, e.g., after one or more cycles of freezing and/or thawing the nucleated cell. In embodiments, the methods comprise contacting an immune cell with a protein nanoparticle comprising an IL-15 complex.
    Type: Grant
    Filed: June 13, 2017
    Date of Patent: October 18, 2022
    Assignee: Torque Therapeutics, Inc.
    Inventors: Ferdinando Pucci, Thomas Lars Andresen, Douglas Scott Jones, Ulrik Nielsen, James Andrew Rakestraw
  • Patent number: 11472842
    Abstract: The present invention provides hepcidin analogues with improved in vivo half lives, and related pharmaceutical compositions and methods of use thereof.
    Type: Grant
    Filed: October 1, 2020
    Date of Patent: October 18, 2022
    Assignee: Protagonist Therapeutics, Inc.
    Inventors: Gregory Thomas Bourne, Mark Leslie Smythe, Brian Troy Frederick, Ashok Bhandari
  • Patent number: 11458206
    Abstract: Nanoparticles and microparticles, and pharmaceutical formulations thereof, containing conjugates of an active agent such as a therapeutic, prophylactic, or diagnostic agent attached to a targeting moiety, such as a somatostatin receptor binding moiety, via a linker have been designed. Such nanoparticles and microparticles can provide improved temporospatial delivery of the active agent and/or improved biodistribution. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer or infectious diseases.
    Type: Grant
    Filed: February 18, 2020
    Date of Patent: October 4, 2022
    Assignee: TVA (ABC), LLC
    Inventors: Rossitza G. Alargova, Mark T. Bilodeau, Craig A. Dunbar, Sudhakar Kadiyala, Rajesh R. Shinde, Patrick Lim Soo, Beata Sweryda-Krawiec, Brian H. White, Patrick Rosaire Bazinet, Richard Wooster
  • Patent number: 11446351
    Abstract: The present invention relates to treating one or more estrogen related diseases while preventing or reducing the likelihood of developing estrogen deficiency related side effects, wherein the composition comprises administering a therapeutically effective amount of a Gn RH antagonist to a patient in need of the treatment, and wherein the amount of Gn RH antagonist is sufficient for providing a mean endogenous serum estradiol level of between about 20 pg/ml and 60 pg/ml, preferably between 30 pg/ml and 50 pg/m, in the patient in a treatment period of at least four weeks, without relying on “add-back” therapy. The composition and method are simple, effective and will accordingly both increase patient acceptance and compliance of therapy.
    Type: Grant
    Filed: April 25, 2019
    Date of Patent: September 20, 2022
    Assignee: LIFEARC
    Inventors: Finn Larsen, Carol Marion Maclean
  • Patent number: 11446268
    Abstract: The present invention provides methods, compositions, and kits for treating anxiety-related disorders, including OCD and SAD, and for reducing anxiety, obsessive behavior, or compulsive behavior in subjects in need thereof.
    Type: Grant
    Filed: January 31, 2020
    Date of Patent: September 20, 2022
    Assignee: YAMO PHARMACEUTICALS LLC
    Inventors: Steven Hoffman, John Rothman
  • Patent number: 11439682
    Abstract: Methods for treating a disorder associated with immunoglobulin E (IgE) in a subject with antibodies capable of binding to the C?mx domain of a membrane-bound IgE. The subject can be administered with at least two doses of the antibody, the two doses being at least three months apart.
    Type: Grant
    Filed: April 29, 2020
    Date of Patent: September 13, 2022
    Assignee: Oneness Biotech Co., Ltd.
    Inventors: Kung-Ming Lu, Nien-Yi Chen, Tien-Tien Cheng
  • Patent number: 11433117
    Abstract: Methods and FSP27 compositions for treating and/or preventing metabolic disease and conditions associated insulin resistance, obesity, inflammation and dyslipidemia are described.
    Type: Grant
    Filed: June 14, 2018
    Date of Patent: September 6, 2022
    Assignee: Ohio University
    Inventors: Vishwajeet Puri, John Kopchick, Vishva Sharma
  • Patent number: 11433112
    Abstract: The present invention is in the fields of medicinal chemistry, biotechnology and pharmaceuticals. The invention provides compositions comprising one or more collagen mimetic peptides, optionally attached to one or more therapeutic compounds or one or more imaging compounds, for use in methods of treating, preventing, ameliorating, curing and diagnosing certain diseases and physical disorders in humans and veterinary animals, as well as methods of manufacturing such composition. The invention also provides medical devices comprising one or more such compositions of the invention.
    Type: Grant
    Filed: May 20, 2022
    Date of Patent: September 6, 2022
    Assignee: SUSTAIN HOLDINGS, LLC
    Inventors: Richard Eric Schlumpf, Robert Baratta, Shawn A. Delorey
  • Patent number: 11435362
    Abstract: The present invention provides a humanized antibody or antibody fragment comprising (a) a humanized light chain comprising 1) Complementarity Determining Region (CDR)-L1, the sequence of which is identical to the sequence of SEQ ID NO: 3; 2) CDR-L2, the sequence of which is identical to the sequence of SEQ ID NO: 4; and 3) CDR-L3, the sequence of which is identical to the sequence of SEQ ID NO: 5, and (b) a humanized heavy chain comprising 1) CDR-H1, the sequence of which is identical to the sequence of SEQ ID NO: 6; 2) CDR-H2, the sequence of which is identical to the sequence of SEQ ID NO: 7; and 3) CDR-H3, the sequence of which is identical to the sequence of SEQ ID NO: 8, as well as methods for treating, diagnosing, and monitoring the progression of HIT. The present invention also provides methods for assessing the antigenicity and ability to cause HIT of anionic anticoagulants.
    Type: Grant
    Filed: June 20, 2019
    Date of Patent: September 6, 2022
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Mark I. Greene, Douglas B. Cines, Zheng Cai, Zhiqiang Zhu
  • Patent number: 11426440
    Abstract: The present invention is in the fields of medicinal chemistry, biotechnology and pharmaceuticals. The invention provides compositions comprising one or more collagen mimetic peptides, optionally attached to one or more therapeutic compounds or one or more imaging compounds, for use in methods of treating, preventing, ameliorating, curing and diagnosing certain diseases and physical disorders in humans and veterinary animals, as well as methods of manufacturing such composition. The invention also provides medical devices comprising one or more such compositions of the invention.
    Type: Grant
    Filed: April 3, 2020
    Date of Patent: August 30, 2022
    Assignee: SUSTAIN HOLDINGS, LLC
    Inventors: Richard Eric Schlumpf, Robert Baratta, Shawn A. Delorey
  • Patent number: 11421012
    Abstract: Analogues of PYY differing from native human PYY by substitution of Ser23 with Ala23, Glu23, Lys23, Gln23 or AIB23. Further optional features include substitutions at further positions, loss of the Tyr1 residue of native human PYY and amidation of the C-terminus. Suitable for use as pharmaceuticals for treating and preventing disorders, in particular diabetes and obesity.
    Type: Grant
    Filed: December 4, 2018
    Date of Patent: August 23, 2022
    Assignee: IP2IPO INNOVATIONS LIMITED
    Inventor: Stephen Robert Bloom
  • Patent number: 11413351
    Abstract: The present invention relates to CNP prodrugs in which the carrier is covalently and reversibly attached to the ring moiety of a CNP moiety, to pharmaceutical compositions comprising such CNP prodrugs, to their uses and to methods of treating diseases that can be treated with the CNP prodrugs of the present invention.
    Type: Grant
    Filed: January 5, 2017
    Date of Patent: August 16, 2022
    Assignee: ASCENDIS PHARMA GROWTH DISORDERS A/S
    Inventors: Harald Rau, Ulrich Hersel, Felix Cleemann, Caroline Elisabeth Rasmussen
  • Patent number: 11407789
    Abstract: In some aspects, the present invention cell-penetrating compstatin analog and compositions comprising cell-penetrating compstatin analog. In some aspects, the invention further provides methods of using cell-penetrating compstatin analogs treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ, to inhibit production or release of biologically active C3 cleavage products.
    Type: Grant
    Filed: December 18, 2020
    Date of Patent: August 9, 2022
    Assignee: Apellis Pharmaceuticals, Inc.
    Inventors: Cedric Francois, Pascal Deschatelets, Monica Gerber
  • Patent number: 11400144
    Abstract: The present invention includes the complete genome sequence for the methanogen, Methanobrevibacter ruminan-tium, including polynucleotides which encode M. ruminantium polypeptides or peptides, as well as polynucleotides from non-coding regions. Also included are the encoded M. ruminantium polypeptides and peptides, and antibodies directed to these peptides or polypeptides, in addition to expression vectors and host cells for producing these peptides, polypeptides, polynucleotides, and antibodies. The invention further includes methods and compositions for detecting, targeting, and inhibiting microbial cells, especially methanogen cells such as M. ruminantium cells, using one or more of the disclosed peptides, polypeptides, polynucleotides, antibodies, expression vectors, and host cells.
    Type: Grant
    Filed: February 23, 2021
    Date of Patent: August 2, 2022
    Assignee: PASTORAL GREENHOUSE GAS RESEARCH LTD.
    Inventors: Eric Heinz Altermann, Graeme Trevor Attwood, Gregory Cook, Debjit Dey, Scott A. Ferguson, Petrus Hendricus Janssen, William John Kelly, Zhanhao Kong, Suzanne Lambie, Sinead Christine Leahy, Dong Li, Duncan McMillan, Sharla McTavish, Diana Pacheco, Robert Starr Ronimus, Carrie Sang, Carl Yeoman